Abingworth oversubscribed at $465m for new life sciences fund Abingworth Bioventures 8

Asante Capital are thrilled to announce the final closing of Abingworth Bioventures 8 (ABV 8) which took place at $465 million, exceeding its target and closing at the hard cap.

Abingworth is a leading international life sciences investment group targeting companies developing innovative therapeutics with potential to significantly improve human health. Abingworth will invest in opportunities in the US, UK and Continental Europe and broadly across multiple stages including seed and early stage, development-stage companies, including VIPEs (Venture Investments in Public Equities), and Clinical Co-development opportunities.  

Asante Capital Group acted as global placement advisor for the fundraise.

To read more, please see below:


Ricardo Felix is Appointed Partner as Hong Kong Team Grows

We're excited to announce that Asante has recently appointed Ricardo Felix, Head of Asia-Pacific, to Partner.

Asante Capital congratulates its partner on the final closing of Harbert Infrastructure Fund VI (‘HIF VI’)

We are pleased to announce the final closing of Harbert Infrastructure Fund VI ( ‘HIF VI’) on September 30, 2022. HIF VI secured $905 million in fund and related co-investment commitments to invest in HIF VI’s portfolio of North American power and renewable energy opportunities. 

Private-Equity Firms Look to Foreign Cash as U.S. Pension Funds Struggle

One of our Managing Partners, Fraser van Rensburg, was quoted in a Wall Street Journal article by Chris Cumming about American private-equity firms collecting more money from abroad.